Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
Blood Research
;
: 115-119, 2014.
Article
in English
| WPRIM
| ID: wpr-217663
ABSTRACT
BACKGROUND:
Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection.METHODS:
We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010.RESULTS:
With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively.CONCLUSION:
These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Radiotherapy
/
Recurrence
/
Lymphoma, Non-Hodgkin
/
B-Lymphocytes
/
Leukemia, Myeloid, Acute
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Lymphoma, B-Cell
/
Disease-Free Survival
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Blood Research
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS